Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

A poster highlighting key data from Amplia's ongoing ACCENT trial is being presented today at the annual meeting of the American Association of Cancer Research (AACR) in Chicago, USA.

The poster,  presented by Amplia’s Director of Translational Science, Dr Terrie-Anne Cock, outlines the scientific rationale for the use of FAK inhibitors in pancreatic cancer treatment, describes the clinical design of the ACCENT trial, and presents a detailed analysis of data up to 7 March 2025 for the first 29 patients of the 55 enrolled in the trial.

The AACR Annual Meeting is the premier forum for cancer research, where leading scientists, clinicians, patients, and advocates convene to share the latest research in cancer science.

Amplia CEO and MD Dr Chris Burns commented:

“The combined data presented today at AACR continues to demonstrate the significant promise narmafotinib, in combination with chemotherapy, has in the treatment of advanced pancreatic cancer. We look forward to presenting more mature data in the coming months for the full cohort of 55 patients.”

ACCENT trial data presented at prestigious international conference 